Natera, Inc. $NTRA Stock: Russell Investments Group Ltd. Reduces Holdings

Russell Investments Group Ltd. lowered its stake in Natera, Inc. (NASDAQ:NTRA – Free Report) by 24.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 125,599 shares of the medical research company’s stock after selling 39,990 shares during the quarter. Russell Investments Group Ltd. owned about 0.09% of Natera worth $51,913,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in NTRA. CENTRAL TRUST Co increased its position in shares of Natera by 13,200.0% during the third quarter. CENTRAL TRUST Co now owns 399 shares of the medical research company’s stock worth $165,000 after acquiring an additional 396 shares in the last quarter. King Luther Capital Management Corp raised its holdings in shares of Natera by 2.6% during the third quarter. King Luther Capital Management Corp now owns 18,836 shares of the medical research company’s stock worth $7,785,000 after acquiring an additional 472 shares during the period. Maryland State Retirement & Pension System lifted its position in Natera by 12.5% in the 3rd quarter. Maryland State Retirement & Pension System now owns 8,260 shares of the medical research company’s stock valued at $3,414,000 after acquiring an additional 920 shares in the last quarter. Ritholtz Wealth Management lifted its position in Natera by 4.3% in the 3rd quarter. Ritholtz Wealth Management now owns 1,726 shares of the medical research company’s stock valued at $713,000 after acquiring an additional 71 shares in the last quarter. Finally, Jefferies Financial Group Inc. lifted its position in Natera by 16.5% in the 3rd quarter. Jefferies Financial Group Inc. now owns 6,355 shares of the medical research company’s stock valued at $2,627,000 after acquiring an additional 898 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NASDAQ NTRA opened at $319.09 on Monday. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41. The company has a market capitalization of $46.27 billion, a PE ratio of -279.90 and a beta of 1.55. The firm’s 50 day moving average is $379.70 and its 200-day moving average is $271.61.

Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The business had revenue of $793.98 million during the quarter, compared to the consensus estimate of $707.54 million. During the same period in the prior year, the firm earned ($0.64) EPS. The business’s revenue for the quarter was up 34.1% compared to the same quarter last year. As a group, sell-side analysts expect that Natera, Inc. will post -1.25 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on NTRA shares. TD Cowen upped their target price on shares of Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. JPMorgan Chase & Co. dropped their price target on Natera from $460.00 to $405.00 and set an “overweight” rating on the stock in a research note on Friday, November 6th. Robert W. Baird cut their price target on Natera from $458.00 to $403.00 and set an “outperform” rating on the stock in a report on Monday, November 9th. UBS Group boosted their price target on Natera from $290.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Finally, Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $394.31.

Read Our Latest Research Report on NTRA

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,419 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the sale, the insider directly owned 101,323 shares of the company’s stock, valued at $41,519,125.71. The trade was a 3.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the transaction, the chief executive officer owned 87,431 shares of the company’s stock, valued at approximately $36,004,085.80. This represents a 4.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 47,056 shares of company stock valued at $17,760,989 over the last quarter. 5.05% of the stock is currently owned by corporate insiders.

Natera Company Profile

(Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

Read More

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.